Felzartamab

DB16375InvestigationalProtein Based Therapies

Felzartamab is under investigation in clinical trial NCT04145440 (Trial to Assess Safety and Efficacy of MOR202 in Anti-pla2r + Membranous Nephropathy (Amn)).

Mechanism: Pharmacologically active on ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
Curator reviewed
Code names: BIIB148 · HIB202 · MOR-03087 · MOR-202 · TJ-202

Resolves to

Compound

UNII3O9FA4XC02CAS2197112-39-1

Targets

P28907CD38

What you can answer from here — as of May 13, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

17Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Felzartamab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account